Literature DB >> 19508162

Mother-to-child transmission of GB virus C in a cohort of women coinfected with GB virus C and HIV in Bangkok, Thailand.

W Bhanich Supapol1, R S Remis, J Raboud, M Millson, J Tappero, R Kaul, P Kulkarni, M S McConnell, P A Mock, J M McNicholl, N Vanprapar, S Asavapiriyanont, N Shaffer, S Butera.   

Abstract

BACKGROUND: GB virus C (GBV-C) is an apathogenic virus that inhibits human immunodeficiency virus (HIV) replication in vitro. Mother-to-child transmission (MTCT) of GBV-C has been observed in multiple small studies. Our study examined the rate and correlates of MTCT of GBV-C in a large cohort of GBV-C-HIV-coinfected pregnant women in Thailand.
METHODS: Maternal delivery plasma specimens from 245 GBV-C-HIV-infected women and specimens from their infants at 4 or 6 months of age were tested for GBV-C RNA. Associations with MTCT of GBV-C were examined using logistic regression.
RESULTS: One hundred one (41%) of 245 infants acquired GBV-C infection. MTCT of GBV-C was independently associated with maternal antiretroviral therapy (adjusted odds ratio [AOR], 5.21 [95% confidence interval {CI}, 2.12-12.81]), infant HIV infection (AOR, 0.05 [95% CI, 0.01-0.26]), maternal GBV-C load (8.0 log(10) copies/mL: AOR, 86.77 [95% CI, 15.27-481.70]; 7.0-7.9 log(10) copies/mL: AOR, 45.62 [95% CI, 8.41-247.51]; 5.0-6.9 log(10) copies/mL: AOR, 9.07 [95% CI, 1.85-44.33]: reference, <5 log(10) viral copies/mL), and caesarean delivery (AOR, 0.26 [95% CI, 0.12-0.59]).
CONCLUSIONS: Associations with maternal GBV-C load and mode of delivery suggest transmission during pregnancy and delivery. Despite mode of delivery being a common risk factor for virus transmission, GBV-C and HIV were rarely cotransmitted. The mechanisms by which maternal receipt of antiretroviral therapy might increase MTCT of GBV-C are unknown.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508162     DOI: 10.1086/599793

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection.

Authors:  Ernest T Chivero; Jack T Stapleton
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

2.  Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients.

Authors:  Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer
Journal:  J Infect Dis       Date:  2014-11-25       Impact factor: 5.226

3.  Current Views on the Pathophysiology of GB Virus C Coinfection with HIV-1 Infection.

Authors:  Esaki Muthu Shankar; Pachamuthu Balakrishnan; Ramachandran Vignesh; Vijayakumar Velu; Palanisamy Jayakumar; Suniti Solomon
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

4.  Target Enrichment Metagenomics Reveals Human Pegivirus-1 in Pediatric Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Natali Ludowyke; Worakorn Phumiphanjarphak; Nopporn Apiwattanakul; Suwimon Manopwisedjaroen; Samart Pakakasama; Insee Sensorn; Ekawat Pasomsub; Wasun Chantratita; Suradej Hongeng; Pakorn Aiewsakun; Arunee Thitithanyanont
Journal:  Viruses       Date:  2022-04-12       Impact factor: 5.818

Review 5.  The role of co-infections in mother-to-child transmission of HIV.

Authors:  Caroline C King; Sascha R Ellington; Athena P Kourtis
Journal:  Curr HIV Res       Date:  2013-01       Impact factor: 1.581

6.  Host factors that influence mother-to-child transmission of HIV-1: genetics, coinfections, behavior and nutrition.

Authors:  Sascha R Ellington; Caroline C King; Athena P Kourtis
Journal:  Future Virol       Date:  2011-11-24       Impact factor: 1.831

7.  Effect of human pegivirus route of transmission on the genetic distribution of the virus: an institution based cross-sectional study.

Authors:  Wubet Taklual; Shixing Tang; Wu Yue
Journal:  Virol J       Date:  2019-04-25       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.